Cilofexor
Metabolic Dysfunction-Associated Steatohepatitis
Explore 128 assets in Metabolic Dysfunction-Associated Steatohepatitis →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Gilead Sciences
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04971785CT.gov Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
NCT03987074CT.gov Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
NCT02854605CT.gov Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH) | — | Completed | — | — | — |
NCT02808312CT.gov Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function | — | Completed | — | — | — |
NCT02654002CT.gov Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatohepatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cilofexor (this asset) | Gilead Sciences | P2 | B · 63 |
| Resmetirom | City University of New York | P4 | BBB |
| Pentoxifylline | Al-Azhar University | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Firsocostat | Gilead Sciences | P2 | BBB |
| Alpha Tocopherol | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Montelukast | Tanta University | P4 | BBB |
| Rosuvastatin | Beni-Suef University | P4 | BBB |
| Ezetimibe | University of Palermo | P4 | BBB |
+42 more in the Metabolic Dysfunction-Associated Steatohepatitis cohort
Other indications for Cilofexor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Sclerosing Cholangitis | — | P3 | B · 59 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | CCC · 53 |
| Primary Biliary Cholangitis | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cilofexor in Metabolic Dysfunction-Associated Steatohepatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cilofexor-metabolic-dysfunction-associated-steatohepatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →